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tion in relation to subsequent statements, therefore appro-
priate clarifications had to be added. The response scale
“very completely, completely, average, incompletely, very
incompletely” was impossible to translate literally. The
following equidistant responses were substituted: “com-
pletely, quite a bit, average, a little bit, not at all.” 
CONCLUSIONS: A rigorous translation methodology
was performed to ensure conceptual equivalence and ac-
ceptability of translations. International feedback obtained
through the translation process revealed issues regarding
the original instrument, indicating that future amend-
ments to the original may be necessary. Psychometric test-
ing will be conducted to ensure reliability and validity of
each translation, appropriateness of the questionnaire in
each country, and comparability of data across countries.
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OBJECTIVE: The purpose of this study was to evaluate
prescribing of opioid analgesics for the treatment of non-
malignant pain conditions. 
METHODS: The 1995 MarketScan® database was used
to identify patients without malignant diagnoses and at
least one prescription for an opioid. The resulting cohort
was classified into three mutually exclusive categories:
transdermal fentanyl (TDF, n  118), long-acting opio-
ids (LA, n  136), and short-acting opioids (SA, n 
92,412). Demographics, diagnosis categories, and re-
source utilization (outpatient, inpatient, and prescription
claims) were examined. 
RESULTS: The number of patients in the SA group was
disproportionately larger than the other groups prevent-
ing a direct comparison. Their average age was 40 years,
primarily female, and 71% working full time. The most
common diagnosis category was musculoskeletal (MSK)
and lumbago was the most frequent condition. For com-
parative purposes, we examined diagnoses groups and re-
source utilization for the TDF and LA groups. Age, gen-
der, and employment status was similar for both groups.
The MSK category and lumbago diagnoses were also the
most common conditions. TDF patients had more lum-
bago physician visits but less cost/patient compared to
the LA group (median 6 visits, $49.50 versus 2.5 visits,
$74.50, respectively). Inpatient use was similar between
groups with a median of two occurrences/patient. The
median prescription use/patient of TDF was slightly less
than LA (3 versus 4.5) and both groups used a similar
number of other opioid analgesics (median  13).
CONCLUSION: This study suggests a similar distribu-
tion of conditions associated with the use of TDF, LA,
and SA opioids. However, SA opioid utilization in non-
malignant pain differs from TDF and LA agents. Further
analysis is necessary to identify characteristics that differ-
entiate these groups.
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OBJECTIVE: The purpose of the study is to compare the
resource utilization and costs related to the total medical
care of Duragesic patients with those incurred by patients
who have been prescribed long-acting opioids. This ab-
stract focuses on the methodology utilized to select a
comparison group for the Duragesic patients.
METHODS: We identified all patients without cancer in
a New England insurer database with at least one pre-
scription for Duragesic from January 1, 1995 through
December 31, 1997. We required each patient to be en-
rolled 30 days prior to the prescription index date and
the ensuing 90 days, and to have drug benefits (n  420).
We similarly identified patients with at least one prescrip-
tion for a long-acting opioid (n  1239). We character-
ized the patients by age, gender, health services utilized,
costs incurred, diagnosis, and drugs dispensed in the 30
days prior the index date.
RESULTS: Duragesic and long-acting opioid patients
had similar distributions of age, sex, and inpatient and
outpatient diagnoses. For both groups, musculoskeletal/
connective tissue conditions were among the most fre-
quent diagnoses, and costs were highest in the month
preceding the first opioid dispensing, dropping by about
50% over the ensuing 90 days.
CONCLUSIONS: Patterns of health resource utilization
and cost are similar for the two groups. Total costs incurred
are highest in the 30 days prior to the initial dispensing and
drop considerably during the following 90 days. There is
overlap among the non-malignant conditions treated with
Duragesic and long-acting opioids. These results suggest
that it may be possible to identify a useful and appropriate
comparison group for the Duragesic patients.
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